Beurskingpin schreef op 9 augustus 2017 01:08:
Survey of Payers and Gastroenterologists Finds Excitement Over the Prospect of JAK Inhibitors to Treat Inflammatory Bowel Disease BURLINGTON, Mass., Aug. 8, 2017 /PRNewswire/ -- Decision Resources Group finds that surveyed health insurance medical and pharmacy directors as well as gastroenterologists look favorably on Janus kinase (JAK) inhibitors for use in Inflammatory Bowel Disease (IBD).
A majority of surveyed payers regarded Pfizer's Xeljanz (tofacitinib) and Gilead/Galapagos' filgotinib as the emerging therapies that will have the greatest impact in ulcerative colitis and Crohn's disease, respectively, and a sizable majority of gastroenterologists expect to prescribe these agents within their first year on the market. An additional finding was that Johnsons and Johnson's Remicade (infliximab) continues to enjoy favorable market access despite the launch of the infliximab biosimilar, Pfizer's Inflectra. Indeed, at the time the survey was fielded, Inflectra had experienced little uptake according to surveyed gastroenterologists. Still, physicians expect that over time, payers will push them to use the biosimilar, and some payers report that they implement utilization management approaches to encourage its use
www.google.be/url?sa=t&source=w ... sORkYCACCQ
Lees meer op:
beursig.com/forum/viewtopic.php?f=4&a...Met dank aan sanderus iex forum